BioMarin Pharmaceuticals
BMRN
BMRN
418 hedge funds and large institutions have $14.8B invested in BioMarin Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 160 increasing their positions, 133 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
418
Holders Change
+4
Holders Change %
+0.97%
% of All Funds
10.42%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.22%
New
62
Increased
160
Reduced
133
Closed
47
Calls
$82.3M
Puts
$75.7M
Net Calls
+$6.61M
Net Calls Change
+$11.7M
Top Buyers
| 1 |
BlackRock
New York
|
+$958M |
| 2 |
Primecap Management
Pasadena,
California
|
+$72.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$71.3M |
| 4 |
Jennison Associates
New York
|
+$55.4M |
| 5 |
ClearBridge Investments
New York
|
+$45.4M |
Top Sellers
| 1 |
JPMorgan Chase & Co
New York
|
-$90.4M |
| 2 |
HM
HealthCor Management
New York
|
-$64.2M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$45.9M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$43.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$36.6M |
